Ignite Creation Date:
2025-12-26 @ 10:37 AM
Ignite Modification Date:
2026-04-13 @ 1:44 PM
Study NCT ID:
NCT01435928
Status:
COMPLETED
Last Update Posted:
2016-04-08
First Post:
2011-09-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
PEARL Schizophrenia Maintenance
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Argentina', 'Bulgaria', 'Croatia', 'Czechia', 'Hungary', 'India', 'Poland', 'Serbia and Montenegro', 'Ukraine']}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069056', 'term': 'Lurasidone Hydrochloride'}], 'ancestors': [{'id': 'D013844', 'term': 'Thiazoles'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D054833', 'term': 'Isoindoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '1-866-503-6351', 'title': 'Medical Director, CNS', 'organization': 'Sunovion'}, 'certainAgreement': {'otherDetails': 'In addition to the \\<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'For the open label phase - all subjects SAEs and AEs were reported over 24 weeks. For the double blind phase, lurasidone and placebo, SAEs and AEs were reported over 28 weeks. The study was stopped once the anticipated number of relapses were reached.', 'eventGroups': [{'id': 'EG000', 'title': 'All Subjects', 'description': 'During the Open Label Phase subjects will receive Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating', 'otherNumAtRisk': 676, 'otherNumAffected': 373, 'seriousNumAtRisk': 676, 'seriousNumAffected': 59}, {'id': 'EG001', 'title': 'Lurasidone', 'description': 'During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily', 'otherNumAtRisk': 144, 'otherNumAffected': 46, 'seriousNumAtRisk': 144, 'seriousNumAffected': 6}, {'id': 'EG002', 'title': 'Placebo', 'description': 'During double blind phase subjects received matching placebo.', 'otherNumAtRisk': 141, 'otherNumAffected': 47, 'seriousNumAtRisk': 141, 'seriousNumAffected': 11}], 'otherEvents': [{'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 79, 'numAffected': 69}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 45, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 31, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 22, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 32, 'numAffected': 28}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 23, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Weight increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 14, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 21, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 116, 'numAffected': 77}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 8, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Akathisia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 104, 'numAffected': 94}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Dystonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 23, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 38, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 28, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Sedation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 27, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 82, 'numAffected': 62}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 10, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 12, 'numAffected': 10}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 43, 'numAffected': 35}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Agitation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 22, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Schizophrenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 11, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Psychotic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}], 'seriousEvents': [{'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Artial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Drug ineffective', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Sudden cardiac death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Therapeutic response delayed', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Intentional overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Facial bones fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Radius fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Toxicity to various agents', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Road traffic accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Hyponytremia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Pin in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Akathasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Transient ischemic attach', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Schizophrenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 20, 'numAffected': 20}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Psychotic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 11, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Suicidal ideation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Acute psychosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Aggression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Agitation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Hallucination, auditory', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Homicidal ideation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Hostility', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Psychiatric decompensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Substance induced psychotic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Suicide attempt', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Acute respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 676, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 144, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 141, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.0'}], 'frequencyThreshold': '3'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Time to First Relapse Event During Double-blind Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median and upper limit of the confidence interval could not be estimated. The median is not estimable for lurasidone because fewer than half of the subjects (43) had first relapse.', 'groupId': 'OG000', 'lowerLimit': '174', 'upperLimit': 'NA'}, {'value': '192', 'comment': 'Upper limit of the confidence interval could not be estimated.', 'groupId': 'OG001', 'lowerLimit': '113', 'upperLimit': 'NA'}]}]}], 'analyses': [{'pValue': '0.039', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.66', 'ciLowerLimit': '0.45', 'ciUpperLimit': '0.98', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEDIAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The Kaplan-Meier method is used for the estimation.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Time to All-cause Discontinuation', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '148', 'comment': 'Upper limit of the confidence interval could not be estimated.', 'groupId': 'OG000', 'lowerLimit': '106', 'upperLimit': 'NA'}, {'value': '115', 'groupId': 'OG001', 'lowerLimit': '82', 'upperLimit': '148'}]}]}], 'analyses': [{'pValue': '0.070', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.75', 'ciLowerLimit': '0.54', 'ciUpperLimit': '1.03', 'statisticalMethod': 'Log Rank', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEDIAN', 'timeFrame': 'Double-blind phase - 28 weeks', 'description': 'The Kaplan-Meier method was used for estimation.', 'unitOfMeasure': 'days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '8.3', 'spread': '1.33', 'groupId': 'OG000'}, {'value': '12.4', 'spread': '1.33', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.029', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'LOCF', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Double-Blind phase - 28 Weeks', 'description': 'The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '0.44', 'spread': '0.087', 'groupId': 'OG000'}, {'value': '0.74', 'spread': '0.087', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.015', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'LOCF', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': "The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '139', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '2.5', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '0.63', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.218', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'LOCF', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'There were four Lurasidone subjects and 2 placebo subjects that had no post-baseline MADRS assessment.'}, {'type': 'SECONDARY', 'title': 'Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '139', 'groupId': 'OG000'}, {'value': '138', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '0.398', 'spread': '0.5354', 'groupId': 'OG000'}, {'value': '-1.341', 'spread': '0.5373', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.021', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'LOCF', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales.\n\nPhysical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline SF-12 assessment.'}, {'type': 'SECONDARY', 'title': 'Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '125', 'groupId': 'OG000'}, {'value': '121', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '0.8', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '0.89', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.056', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'LOCF', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'There were 19 Lurasidone subjects and 20 placebo subjects that had no post-baseline assessment.'}, {'type': 'SECONDARY', 'title': 'Brief Adherence Rating Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '139', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '98.8', 'spread': '4.42', 'groupId': 'OG000'}, {'value': '98.9', 'spread': '3.66', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.', 'unitOfMeasure': 'percentage of monthly doses taken', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'There were 6 Lurasidone subjects and 2 placebo subjects that had no post-baseline assessment.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'EuroQol (EQ-5D): EQ-VAS Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '139', 'groupId': 'OG000'}, {'value': '138', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '74.5', 'spread': '19.87', 'groupId': 'OG000'}, {'value': '68.2', 'spread': '28.59', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating.\n\nThe 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline assessment.'}, {'type': 'SECONDARY', 'title': 'Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '10.0', 'spread': '12.76', 'groupId': 'OG000'}, {'value': '8.2', 'spread': '8.97', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '28 Weeks - Double Blind Phase', 'description': 'Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.', 'unitOfMeasure': 'number of cigarettes smoked daily', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Subjects who smoked'}, {'type': 'SECONDARY', 'title': 'Intent to Attend (ITA) Assessment at Open-label Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '140', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating\n\nLurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating\n\nMatching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating'}], 'classes': [{'categories': [{'measurements': [{'value': '7.9', 'spread': '1.48', 'groupId': 'OG000'}, {'value': '8.0', 'spread': '1.47', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Open Label Baseline', 'description': 'The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: "How likely is it that you will complete the study?"', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All subjects who were randomized and received at least one dose of study medication in the double-blind phase. Subjects were analyzed based on the treatment they were randomized.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'All Subjects', 'description': 'During the Open Label Phase subjects will receive Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating'}, {'id': 'FG001', 'title': 'Lurasidone', 'description': 'During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily'}, {'id': 'FG002', 'title': 'Placebo', 'description': 'During double blind phase subjects received matching placebo.'}], 'periods': [{'title': 'Open Label Phase - up to 24 Weeks', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '676'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '287'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '389'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '83'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '46'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '60'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '96'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'did not meet stabilization criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '44'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Terminated at study completion', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Administrative', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}, {'title': 'Double Blind Phase - 28 Weeks', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '144'}, {'groupId': 'FG002', 'numSubjects': '141'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '28'}, {'groupId': 'FG002', 'numSubjects': '20'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '116'}, {'groupId': 'FG002', 'numSubjects': '121'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '5'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '11'}, {'groupId': 'FG002', 'numSubjects': '4'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '12'}]}, {'type': 'Terminated at study completion', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '47'}, {'groupId': 'FG002', 'numSubjects': '39'}]}, {'type': 'Relapse criteria met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '43'}, {'groupId': 'FG002', 'numSubjects': '58'}]}, {'type': 'Administrative', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '2'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'BG000'}, {'value': '141', 'groupId': 'BG001'}, {'value': '285', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Lurasidone', 'description': 'During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'During double blind phase subjects received matching placebo.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.0', 'spread': '11.38', 'groupId': 'BG000'}, {'value': '42.4', 'spread': '12.25', 'groupId': 'BG001'}, {'value': '42.7', 'spread': '11.80', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '142', 'groupId': 'BG000'}, {'value': '140', 'groupId': 'BG001'}, {'value': '282', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '54', 'groupId': 'BG000'}, {'value': '53', 'groupId': 'BG001'}, {'value': '107', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '90', 'groupId': 'BG000'}, {'value': '88', 'groupId': 'BG001'}, {'value': '178', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '72', 'groupId': 'BG000'}, {'value': '62', 'groupId': 'BG001'}, {'value': '134', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '65', 'groupId': 'BG000'}, {'value': '71', 'groupId': 'BG001'}, {'value': '136', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '137', 'groupId': 'BG000'}, {'value': '132', 'groupId': 'BG001'}, {'value': '269', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'France', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}, {'title': 'Serbia', 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '103', 'groupId': 'BG000'}, {'value': '97', 'groupId': 'BG001'}, {'value': '200', 'groupId': 'BG002'}]}]}, {'title': 'Slovakia', 'categories': [{'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}]}]}, {'title': 'Russian Federation', 'categories': [{'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}]}, {'title': 'South Africa', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '21', 'groupId': 'BG002'}]}]}, {'title': 'Italy', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 676}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-03', 'completionDateStruct': {'date': '2013-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-03-10', 'studyFirstSubmitDate': '2011-09-15', 'resultsFirstSubmitDate': '2014-07-25', 'studyFirstSubmitQcDate': '2011-09-16', 'lastUpdatePostDateStruct': {'date': '2016-04-08', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-09-09', 'studyFirstPostDateStruct': {'date': '2011-09-19', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-09-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'EuroQol (EQ-5D): EQ-VAS Score', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating.\n\nThe 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.'}], 'primaryOutcomes': [{'measure': 'Time to First Relapse Event During Double-blind Phase', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The Kaplan-Meier method is used for the estimation.'}], 'secondaryOutcomes': [{'measure': 'Time to All-cause Discontinuation', 'timeFrame': 'Double-blind phase - 28 weeks', 'description': 'The Kaplan-Meier method was used for estimation.'}, {'measure': 'Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score', 'timeFrame': 'Double-Blind phase - 28 Weeks', 'description': 'The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.'}, {'measure': 'Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': "The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity."}, {'measure': 'Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.'}, {'measure': 'Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales.\n\nPhysical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.'}, {'measure': 'Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.'}, {'measure': 'Brief Adherence Rating Scale', 'timeFrame': 'Double-blind phase - 28 Weeks', 'description': 'The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.'}, {'measure': 'Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)', 'timeFrame': '28 Weeks - Double Blind Phase', 'description': 'Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.'}, {'measure': 'Intent to Attend (ITA) Assessment at Open-label Baseline', 'timeFrame': 'Open Label Baseline', 'description': 'The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: "How likely is it that you will complete the study?"'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Schizophrenia', 'Lurasidone', 'Latuda'], 'conditions': ['Schizophrenia']}, 'descriptionModule': {'briefSummary': 'Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nOpen Label:\n\nSubject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.\n\nSubject is ≥ 18 and ≤ 75 years of age, on the day of signing the informed consent.\n\nSubject meets DSM-IV-TR criteria for a primary diagnosis of schizophrenia \\[including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes as established by clinical interview (using the DSM-IV-TR as a reference and confirmed using the SCID-CT)\\]. The duration of the subject\'s illness whether treated or untreated must be ≥ 1 year.\n\nSubject has had at least one prior episode of psychotic exacerbation as judged by the Investigator in the two years preceding screening.\n\nSubject has a PANSS Total score ≥ 80 with a score ≥ 4 on 1 or more of any PANSS Positive subscale items at screening and open-label baseline (Visit 2).\n\nSubject has a CGI-S score of ≥ 4 at screening and open-label baseline (Visit 2).\n\nSubject is not pregnant (must have a negative serum pregnancy test at screening) or nursing (must not be lactating) and is not planning pregnancy within the projected duration of the study.\n\nFemale subject of reproductive potential agrees to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of lurasidone has been taken. In the Investigator\'s judgment, the subject will adhere to this requirement.\n\nAdequate contraception is defined as continuous use of either two barrier methods (e.g., condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive. Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening.\n\nSubjects who are of non-reproductive potential, i.e., subject who is surgically sterile, has undergone tubal ligation, or is postmenopausal (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis) are not required to remain abstinent or use adequate contraception.\n\nSubject is able and agrees to remain off prior antipsychotic medication for the duration of the study.\n\nSubject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge, if hospitalized. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (e.g., due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.\n\nSubject is in good physical health on the basis of medical history, physical examination, and laboratory screening.\n\nSubject who requires concomitant medication treatment with the following agents may be included if they have been on stable doses (i.e., minor adjustments only) for the specified times: 1) antidepressant agents (except fluvoxamine) and/or mood stabilizers (except carbamazepine or oxcarbazepine) must be stable for at least 30 days prior to open-label baseline, 2) oral hypoglycemics must be stable for at least 30 days prior to screening, 3) antihypertensive agents must be stable for at least 30 days prior to screening, and 4) thyroid hormone replacement must be stable for at least 90 days prior to screening. (Note: CYP3A4 inducers and inhibitors will not be allowed).\n\nSubject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator.\n\nDouble-blind -\n\nSubject must achieve and maintain clinical stability for a total of at least 12 weeks in the open label phase, defined as:\n\n1. a PANSS Total score ≤ 70, a CGI-S score \\< 4 and a PANSS item score of ≤ 4 (moderate or less) on all PANSS Positive subscale items over at least 12 weeks with the allowance of two excursions (except during the last 4 weeks of the open-label phase) assessed at weekly study visits:\n\n • An excursion is defined as a PANSS total score up to a maximum of 80 and/or a CGI-S score up to a maximum of 4 and/or a PANSS Positive subscale item score up to a maximum of 5.\n2. a PANSS item score of ≤ 4 (moderate or less) on item G8 (uncooperativeness)\n3. taking a stable dose of lurasidone for the last 4 weeks of the open-label phase.\n\nExclusion Criteria:\n\nOpen Label - Subject has a DSM-IV Axis I or Axis II diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.\n\nSubject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (in the past month) or baseline.\n\nSubject has attempted suicide within 3 months prior to the screening phase. Subject currently has a clinically significant medical condition including the following: neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorder such as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study. Subjects with human immunodeficiency virus (HIV) seropositivity (or history of seropositivity) will be excluded.\n\nNote: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor before being screened.\n\nSubject has evidence of any chronic organic disease of the CNS such as tumors, inflammation, and active seizure disorder, vascular disorder, Parkinson\'s disease, Alzheimer\'s disease or other forms of dementia, myasthenia gravis, or other degenerative processes. In addition, subject must not have a history of mental retardation or persistent neurological symptoms attributable to serious head injury. Note: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.\n\nNote: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.\n\nSubject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.\n\nNote: Subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, such subjects will be discussed with the Medical Monitor for enrollment consideration.\n\nSubject has a history of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug.\n\nSubject with Type 1 or Type 2 insulin-dependent diabetes.\n\nSubject with newly diagnosed Type 2 diabetes during screening. Subject with Type 2 diabetes is eligible for study inclusion if the following condition is met at screening:\n\nif a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.\n\nSubject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or HbA1c ≥ 7.0% will be excluded.\n\nNote: Subjects with random (non-fasting) blood glucose at screening ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state.\n\nSubject has a prolactin concentration \\> 100 ng/mL at screening or has a history of pituitary adenoma.\n\nSubject has a history of malignancy \\< 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.\n\nSubject is judged to be resistant to antipsychotic treatment defined as any one of the following:\n\n1. failure to respond to \\> 2 marketed antipsychotic agents, given at an adequate dose and for an adequate duration (within the past 2 years)\n2. history of treatment with clozapine for refractory psychosis Subject is unlikely to achieve a stable condition for ≥ 12 weeks during the open-label lurasidone phase based on the totality of evidence from the psychiatric history and/or the current presentation.\n\nSubject is receiving an antipsychotic medication above the maximum recommended (country-specific) dose at or prior to screening and, in the judgment of the Investigator, is unlikely to respond to standard doses of lurasidone.\n\nSubject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer) prior to the screening phase.\n\nSubject has received treatment with MAO inhibitors within 14 days prior to the screening phase.\n\nSubject requires treatment with any potent CYP3A4 inhibitors or inducers during the study (see Appendix 3).\n\nSubject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require electroconvulsive therapy (ECT) during the study.\n\nSubject has a history of neuroleptic malignant syndrome. Subject exhibits evidence of severe tardive dyskinesia, severe dystonia, or any other severe movement disorder. Severity will be determined by the Investigator.\n\nSubject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.\n\nSubject tests positive for drugs of abuse at screening. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject\'s ability to abstain from using this drug during the study. This information will be discussed with the Medical Monitor prior to study enrollment.\n\nSubject had a history or presence of an abnormal electrocardiogram (ECG), which in the Investigator\'s opinion is clinically significant (Medical Monitor may be consulted to determine clinical significance).\n\nSubject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator.\n\nSubject has a history of hypersensitivity to more than 2 distinct chemical classes of drug (e.g., sulfas and penicillins).\n\nSubject was screened or washed out previously more than three times for this study.\n\nSubject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent, or has participated in 2 or more studies within 12 months prior to signing the informed consent.\n\nSubject is homeless or did not have a stable residence for the 3 months prior to the screening phase.\n\nSubject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or was planning to relocate during the study.\n\nSubject requires guardianship under the laws of his/her country.\n\nDouble-blind - Subjects who in the Investigator\'s judgment have not been compliant with study medication during the open-label stabilization phase.'}, 'identificationModule': {'nctId': 'NCT01435928', 'briefTitle': 'PEARL Schizophrenia Maintenance', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sumitomo Pharma America, Inc.'}, 'officialTitle': 'A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia', 'orgStudyIdInfo': {'id': 'D1050238'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Lurasidone', 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating', 'interventionNames': ['Drug: Lurasidone']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating', 'interventionNames': ['Drug: Matching Placebo']}], 'interventions': [{'name': 'Lurasidone', 'type': 'DRUG', 'otherNames': ['Latuda'], 'description': 'Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating', 'armGroupLabels': ['Lurasidone']}, {'name': 'Matching Placebo', 'type': 'DRUG', 'description': 'Matching placebo once daily in the evening with a meal or 30 minutes after eating', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72764', 'city': 'Springdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Woodland Research Northwest'}, {'zip': '72201', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'K&S Professional Research', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '72211', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Woodland International Research Group', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '90703', 'city': 'Cerritos', 'state': 'California', 'country': 'United States', 'facility': 'Comprehensive Clinical Development Inc.', 'geoPoint': {'lat': 33.85835, 'lon': -118.06479}}, {'zip': '90241', 'city': 'Downey', 'state': 'California', 'country': 'United States', 'facility': 'Diligent Clinical Trials', 'geoPoint': {'lat': 33.94001, 'lon': -118.13257}}, {'zip': '92025', 'city': 'Escondido', 'state': 'California', 'country': 'United States', 'facility': 'Synergy Escondido', 'geoPoint': {'lat': 33.11921, 'lon': -117.08642}}, {'zip': '92845', 'city': 'Garden Grove', 'state': 'California', 'country': 'United States', 'facility': 'Collaborative Neuroscience Network, Inc.', 'geoPoint': {'lat': 33.77391, 'lon': -117.94145}}, {'zip': '90036', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Axis Clinical Trials', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '91950', 'city': 'National City', 'state': 'California', 'country': 'United States', 'facility': 'Synergy Clinical Research Center', 'geoPoint': {'lat': 32.67811, 'lon': -117.0992}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'Excell Clinical Trials', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '90660', 'city': 'Pico Rivera', 'state': 'California', 'country': 'United States', 'facility': 'CNRI - Los Angeles LLC,8309 Telegraph Road', 'geoPoint': {'lat': 33.98307, 'lon': -118.09673}}, {'zip': '92102', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'California Neuropsychopharmacology Clinical Research Instit', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92701', 'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'facility': 'Neuropsychiatric Research Center of Orange County', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'zip': '90502', 'city': 'Torrance', 'state': 'California', 'country': 'United States', 'facility': 'Collaborative Neuroscience Network Inc.', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'zip': '34208', 'city': 'Bradenton', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Clinical Research Center, LLC', 'geoPoint': {'lat': 27.49893, 'lon': -82.57482}}, {'zip': '34742', 'city': 'Kissimme', 'state': 'Florida', 'country': 'United States', 'facility': 'Accurate Clinical Trials'}, {'zip': '32751', 'city': 'Maitland', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Clinical Research Center, LLC', 'geoPoint': {'lat': 28.62778, 'lon': -81.36312}}, {'zip': '33166', 'city': 'Miami Springs', 'state': 'Florida', 'country': 'United States', 'facility': 'Galiz Research', 'geoPoint': {'lat': 25.82232, 'lon': -80.2895}}, {'zip': '32763', 'city': 'Orange City', 'state': 'Florida', 'country': 'United States', 'facility': 'Medical Research Group of Central Florida', 'geoPoint': {'lat': 28.94888, 'lon': -81.29867}}, {'zip': '30308', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Atlanta Center for Medical Research', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30328', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Comprehensive NeuroScience, Inc.', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '70629', 'city': 'Lake Charles', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Lake Charles Clinical Trials', 'geoPoint': {'lat': 30.21309, 'lon': -93.2044}}, {'zip': '71104', 'city': 'Shreveport', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Lousiana Clinical Research, LLC', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '20850', 'city': 'Rockville', 'state': 'Maryland', 'country': 'United States', 'facility': 'CBH Health LLC', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'zip': '63368', 'city': "O'Fallon", 'state': 'Missouri', 'country': 'United States', 'facility': 'Psychiatric Care and Research Center', 'geoPoint': {'lat': 38.81061, 'lon': -90.69985}}, {'zip': '63128', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Psych Care Consultants Research', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '89102', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'Horne Research', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89128', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'Center for Psychiatry and Behavioral Medicine, Inc.', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '08046', 'city': 'Willingboro', 'state': 'New Jersey', 'country': 'United States', 'facility': 'CRI Worldwide LLC', 'geoPoint': {'lat': 40.02789, 'lon': -74.86905}}, {'zip': '14218', 'city': 'Buffalo', 'state': 'New York', 'country': 'United States', 'facility': 'University of New York, Dept. of Psychiatry', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'zip': '11516', 'city': 'Cedarhurst', 'state': 'New York', 'country': 'United States', 'facility': 'Neurobehavioral Research, Inc.', 'geoPoint': {'lat': 40.62288, 'lon': -73.7243}}, {'zip': '11366', 'city': 'Fresh Meadows', 'state': 'New York', 'country': 'United States', 'facility': 'Comprehensive Clinical Development, Inc', 'geoPoint': {'lat': 40.73482, 'lon': -73.79347}}, {'zip': '14618', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'Finger Lakes Clinical Research', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '10305', 'city': 'Staten Island', 'state': 'New York', 'country': 'United States', 'facility': 'Behavioral Medical Research of Staten Island', 'geoPoint': {'lat': 40.56233, 'lon': -74.13986}}, {'zip': '73116', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Cutting Edge Research Group', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '73116', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Oklahoma Clinical Research', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '19139', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'CRI Worldwide LLC at Kirkbride', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '02865', 'city': 'Lincoln', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'Lincoln Research', 'geoPoint': {'lat': 41.92111, 'lon': -71.435}}, {'zip': '78754', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Community Clinical Research, Inc.', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '78756', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'FutureSearch Clinical Trials LP', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'FutureSearch Clinical Trials, LP', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75243', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Pillar Clinical Research LLC', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77381', 'city': 'The Woodlands', 'state': 'Texas', 'country': 'United States', 'facility': 'Family Psychiatry of the Woodlands', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '84132', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Department of Psychiatry, University of Utah Health Sciences Center', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '99204', 'city': 'Spokane', 'state': 'Washington', 'country': 'United States', 'facility': 'Frontier Institute', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': '63003', 'city': 'Clermont-Ferrand', 'country': 'France', 'facility': 'CHU Clermont-Ferrand - CMP B', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '39100', 'city': 'Dole', 'country': 'France', 'facility': 'Centre Hospitalier Specialise du Jura - Centre Medico Psychiatric', 'geoPoint': {'lat': 47.09225, 'lon': 5.48966}}, {'zip': '35703', 'city': 'Rennes', 'country': 'France', 'facility': 'Centre Hospitalier Guillaume Regnier', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '83000', 'city': 'Toulon', 'country': 'France', 'facility': 'Hopital Chalucet, Centre hospitalier intercommunal de toulon la Seyne sur mer (CHITS)', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'zip': '31200', 'city': 'Toulouse', 'country': 'France', 'facility': 'Cabinet Medical', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '19123', 'city': 'La Spezia', 'country': 'Italy', 'facility': 'SC SPDC-Edificio n. 7, Ospedale S. Andrea', 'geoPoint': {'lat': 44.103, 'lon': 9.82375}}, {'zip': '54100', 'city': 'Massa', 'country': 'Italy', 'facility': 'Dipartimento Salute Mentale ASL 1', 'geoPoint': {'lat': 44.03541, 'lon': 10.13927}}, {'zip': '56100', 'city': 'Pisa', 'country': 'Italy', 'facility': 'A.O.U. Santa Chiara, U.O di Psichiatria 1 building n.4', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '399083', 'city': 'Lipetsk', 'country': 'Russia', 'facility': 'Regional Government Institution Kipetsk Regional Psychoneurology Hospital', 'geoPoint': {'lat': 52.5876, 'lon': 39.55151}}, {'zip': '344000', 'city': 'Rostov-on-Don', 'country': 'Russia', 'facility': 'Limited Liability Company (LLC) Research Center for Treatment and rehabilitation "Phoenix"', 'geoPoint': {'lat': 47.21997, 'lon': 39.70769}}, {'zip': '190005', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'City Psychoneurological Dispensary #7 (with Hospital)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '19005', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'St. Petersburg State Budgetary Healthcare Institution City Psychoneurology Dispensary #7 (with in-patient dept.) (SPb SBHI CPNDD-7), at daycare facility #1', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '191167', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'St. Petersburg State Healthcare Institution (SPbSH) "City Psychiatric Hospital #6"', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '19119', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'St. Petersburg State Government Healthcare Institution City Psychiatric Hospital #4 (St. Petersburg Insane Asylum Distributor)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Institute of Mental Health', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Military Medical Academy, Clinic for Psychiatry', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '34000', 'city': 'Kragujevac', 'country': 'Serbia', 'facility': 'Clinical Centre Kragujevac, Clinic for Psychiatry', 'geoPoint': {'lat': 44.01667, 'lon': 20.91667}}, {'zip': '18000', 'city': 'Niš', 'country': 'Serbia', 'facility': 'Clinical Centre Nis, Clinic for mental health protection', 'geoPoint': {'lat': 43.32472, 'lon': 21.90333}}, {'zip': "23330'", 'city': 'Novi Kneževac', 'country': 'Serbia', 'facility': 'Specialized Hospital for psychiatric diseases "Sveti Vracevi"', 'geoPoint': {'lat': 46.05, 'lon': 20.1}}, {'zip': '21000', 'city': 'Novi Sad', 'country': 'Serbia', 'facility': 'Clinical Centre Vojvodina, Clinic for Psychiatry', 'geoPoint': {'lat': 45.25167, 'lon': 19.83694}}, {'zip': '972 01', 'city': 'Bojnice', 'country': 'Slovakia', 'facility': 'Nemonnica s poliklinikou v Prievidzi so sidlom v Bojniciach, Psychiatricke oddelenie', 'geoPoint': {'lat': 48.78511, 'lon': 18.5864}}, {'zip': '82007', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Psychiatricka ambulancia Mentum, s.r.o.', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '071 01', 'city': 'Michalovce', 'country': 'Slovakia', 'facility': 'Psychiatricka nemocnica Michalovce', 'geoPoint': {'lat': 48.75434, 'lon': 21.9195}}, {'zip': '97901', 'city': 'Rimavská Sobota', 'country': 'Slovakia', 'facility': 'PsychoLine s.r.o. Psychiatricka ambulancia', 'geoPoint': {'lat': 48.38284, 'lon': 20.02239}}, {'zip': '97912', 'city': 'Rimavská Sobota', 'country': 'Slovakia', 'facility': 'Psychiaticke oddelenie Vseobecna nemocnica Riimavska Sobota, NaP n.o.', 'geoPoint': {'lat': 48.38284, 'lon': 20.02239}}, {'zip': '048 01', 'city': 'Rožňava', 'country': 'Slovakia', 'facility': 'Psychiatricke oddelenie, Nemocnica s poliklinikou sv. Barbory Roznava, a.s.', 'geoPoint': {'lat': 48.66009, 'lon': 20.53758}}, {'zip': '08901', 'city': 'Svidník', 'country': 'Slovakia', 'facility': 'Centrum zdravia R. B.K. s.r.o. Psychiatricka ambulancia', 'geoPoint': {'lat': 49.30819, 'lon': 21.5703}}, {'zip': '9300', 'city': 'Bloemfontein', 'country': 'South Africa', 'facility': 'Research Unit, Department of Psychiatry Free State Psychiatric Complex', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}, {'zip': '7530', 'city': 'Cape Town, W. Cape', 'country': 'South Africa', 'facility': 'Cape Trial Centre', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '0081', 'city': 'Pretoria', 'country': 'South Africa', 'facility': 'Denmar Hospital Consulting Rooms', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}], 'overallOfficials': [{'name': 'Medical Director, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Sumitomo Pharma America, Inc.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sumitomo Pharma America, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}